Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 10, 2008

Wyeth Decides to End Cardiovascular Research Collaboration with Curis

  • Wyeth has decided to axe development efforts on the Hedgehog agonist program with Curis, which is still in the preclinical phase. The partnership will conclude on May 6.

    Under the original agreement, which was entered into in January 2004, Curis licensed its Hedgehog protein and small molecule pathway agonists to Wyeth. The firms focused preclinical R&D on stroke and cardiovascular disease treatments.

    “We remain hopeful about the future prospects of the Hedgehog agonist as a potential therapeutic for various diseases and we will seek a new partner to continue advancing this program,” remarks Daniel R. Passeri, president and CEO of Curis. “Our internal data and third-party publications suggest that Hedgehog agonists may provide therapeutic benefit in several disease areas including neurological, cardiovascular, and bone disorders as well as for wound healing and hair growth.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »